CEACAM20

Across TCGA pan-cancer cohorts, CEACAM20 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CEACAM20 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CEACAM20 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEACAM20 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, SKCM, and LUSC are the cancer types where CEACAM20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.710	.002	36	view →
SKCM	DFS	Median	III,IV	0.890	0.559	.012	15	view →
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CEACAM20–HNSC (OS)

Open the HNSC breakdown →